Public Summary

Summary for ARTG Entry:	222229	Blackmores Ginkgo 6000 mg Tebonin EGb 761
ARTG entry for	Medicine Listed	
Sponsor	Blackmores Ltd	
Postal Address	PO Box 1725, WARRIEWOOD, NSW, 2102 Australia	
ARTG Start Date	9/04/2014	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

The Ginkgo biloba leaf extract used in the manufacture of this medicine must comply with the requirement of Identification Test B of the monograph Powdered Ginkgo Extract in the United States Pharmacopeia 32 - National Formulary 27 (USP32-NF27) as in force or existing from time to time. This condition does not apply to powdered or dried leaf.

Products

1 . Blackmores Ginkgo 6000 mg Tebonin EGb 761

Product Type Single Medicine Product **Effective Date** 10/09/2020

Permitted Indications

Antioxidant/Reduce free radicals formed in the body

Maintain/support healthy blood circulation

Maintain/support cognitive function/mental function

Maintain/support memory/mental recall

Indication Requirements

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to serious cardiovascular conditions.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Contains lactose (or words to that effect).

If symptoms persist consult your healthcare practitioner (or words to that effect).

(If medicine contains one sugar) contains [insert name of sugar] OR (If medicine contains two or more sugars) Contains sugars [or words to that effect].

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule

Components

1 . Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	

Active Ingredients

Ginkgo biloba leaf Extract dry concentrate standardised	**120 mg**
Equivalent: Ginkgo biloba (Dry)	6 g

Other Ingredients (Excipients)

croscarmellose sodium
hypromellose
iron oxide red
lactose monohydrate
macrogol 1500
magnesium stearate
maize starch
microcrystalline cellulose
purified talc
silicon dioxide
titanium dioxide